공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

인터페론 알파(IFNA) : 파이프라인 리뷰

Interferon Alpha (IFNA) - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 12월 상품 코드 422322
페이지 정보 영문 47 Pages
가격
US $ 3,500 ₩ 4,037,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,074,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,111,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


인터페론 알파(IFNA) : 파이프라인 리뷰 Interferon Alpha (IFNA) - Pipeline Review, H2 2016
발행일 : 2016년 12월 페이지 정보 : 영문 47 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

인터페론 알파(IFNA: Interferon Alpha)를 표적으로 한 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

  • 조사 범위

인터페론 알파(IFNA) 개요

치료제 개발

  • 개발중인 제품 : 개발 단계별
  • 개발중인 제품 : 치료 영역별
  • 개발중인 제품 : 증상별

파이프라인 제품 상황 개요

  • 후기 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

치료제 평가

  • 단독치료 제품/병용요법 제품별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여기업

  • Argos Therapeutics Inc
  • Neovacs SA
  • PsiOxus Therapeutics Ltd
  • ZIOPHARM Oncology Inc

약제 개요

  • AGS-009
  • Biosimilar to Inhibit Interferon Alpha for Lupus Erythematosus
  • NG-345
  • RTS-IFN Alpha
  • Vaccine to Target IFN-Alpha for Chronic Viral Infections, Dermatomyositis and Systemic Lupus Erythematosus

휴지 상태인 프로젝트

개발이 중지된 제품

주요 뉴스 및 프레스 릴리스

부록

도표

LSH 17.02.27

Summary

Global Markets Direct's, 'Interferon Alpha (IFNA) - Pipeline Review, H2 2016', provides in depth analysis on Interferon Alpha (IFNA) targeted pipeline therapeutics.

The report provides comprehensive information on the Interferon Alpha (IFNA) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interferon Alpha (IFNA) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Interferon Alpha (IFNA)
  • The report reviews Interferon Alpha (IFNA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interferon Alpha (IFNA) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interferon Alpha (IFNA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interferon Alpha (IFNA) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interferon Alpha (IFNA)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interferon Alpha (IFNA) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interferon Alpha (IFNA) Overview
  • Therapeutics Development
    • Interferon Alpha (IFNA) - Products under Development by Stage of Development
    • Interferon Alpha (IFNA) - Products under Development by Therapy Area
    • Interferon Alpha (IFNA) - Products under Development by Indication
  • Interferon Alpha (IFNA) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Interferon Alpha (IFNA) - Products under Development by Companies
  • Interferon Alpha (IFNA) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Interferon Alpha (IFNA) - Companies Involved in Therapeutics Development
    • Argos Therapeutics Inc
    • Neovacs SA
    • PsiOxus Therapeutics Ltd
    • ZIOPHARM Oncology Inc
  • Interferon Alpha (IFNA) - Drug Profiles
    • AGS-009 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biosimilar to Inhibit Interferon Alpha for Lupus Erythematosus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NG-345 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RTS-IFN Alpha - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target IFN-Alpha for Chronic Viral Infections, Dermatomyositis and Systemic Lupus Erythematosus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Interferon Alpha (IFNA) - Dormant Projects
  • Interferon Alpha (IFNA) - Discontinued Products
  • Interferon Alpha (IFNA) - Featured News & Press Releases
    • Dec 07, 2016: Neovacs obtains FDA "Fast Track" designation for IFNa Kinoid in Lupus (SLE)
    • Nov 23, 2016: 3P Biopharmaceuticals signs production partnership with Neovacs
    • Nov 07, 2016: Neovacs enrolls the first U.S. Patient in Phase IIb study of IFNa Kinoid for treatment of Systemic Lupus Erythematosus
    • Oct 12, 2016: Neovacs signs a cooperation agreement with the Department Immunology of Diabetes at the reputed Hospital Cochin in Paris
    • Apr 28, 2016: Neovacs obtains FDA approval to extend its Phase IIb clinical trial in Lupus to United States
    • Apr 14, 2016: Neovacs obtains South Korea health authority approval for IND application with IFNa kinoid in Lupus
    • Jan 06, 2016: Neovacs Secures €5 Million, from the Public Funding Program to Support Clinical and Industrial Development for the Therapeutic Vaccine INFa Kinoid
    • Sep 24, 2015: Neovacs initiates phase IIb trial of IFNa-Kinoid for the treatment of lupus
    • Sep 17, 2015: Stellar Biotechnologies' Partner Neovacs Reports Potent and Long-Lasting Biological Activity of IFN-Alpha-Kinoid Immunotherapy 4 Years After Patient Dosing in Lupus Phase I/IIa Trial
    • Sep 09, 2015: Neovacs confirms potent and long-lasting biological activity of IFNa-Kinoid 4 years after patient dosing in phase I/IIa trial
    • Sep 01, 2015: Neovacs Receives First Regulatory Approvals for a Phase IIb Trial of IFNa-Kinoid in Lupus
    • Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis
    • Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis
    • May 13, 2015: Neovacs granted 1.8 million euros in research tax credit
    • Apr 01, 2015: Stellar Biotechnologies and Neovacs S.A. Expand KLH Supply Relationship
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Argos Therapeutics Inc, H2 2016
  • Pipeline by Neovacs SA, H2 2016
  • Pipeline by PsiOxus Therapeutics Ltd, H2 2016
  • Pipeline by ZIOPHARM Oncology Inc, H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top
전화 문의
F A Q